Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma

E Frei, C Visco, Z Y Xu-Monette, S Dirnhofer, K Dybkær, A Orazi, G Bhagat, E D Hsi, J H van Krieken, M Ponzoni, R S Go, M A Piris, M B Møller, K H Young, A Tzankov

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI). Data on the prognostic role of CCNE in the 'rituximab (R)-era' are lacking.
Original languageEnglish
JournalJournal of Clinical Pathology
Volume66
Issue number11
Pages (from-to)956-961
ISSN0021-9746
DOIs
Publication statusPublished - 2013

Keywords

  • Aged
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Cohort Studies
  • Cyclin E
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Lymphoma, Large B-Cell, Diffuse
  • Male
  • Middle Aged
  • Oncogene Proteins
  • Prednisone
  • Prognosis
  • Reproducibility of Results
  • Tissue Array Analysis
  • Treatment Outcome
  • Vincristine

Fingerprint Dive into the research topics of 'Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this